Drugs · acquisition-cost intelligence
E.E.S
Erythromycin· ingredient erythromycinAntibiotics· ERYTHROMYCIN ETHYLSUCCINATE 200 mg/5mL; ERYTHROMYCIN ETHYLSUCCINATE 400 mg/1; ERYTHROMYCIN ETHYLSUCCINATE 400 mg/5mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per ML
$1.59
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per ML — the trend nobody else shows. 7 weeks.
2025-01-222026-05-20
Same-ingredient options by acquisition cost
Other erythromycin products, cheapest acquisition cost first. Per ML — confirm strength/form equivalence before switching.
| Product | NADAC / ML | vs this |
|---|---|---|
| erythromycin | $0.34583 | −$1.25 |
| Erythromycin | $0.66199 | −$0.93020 |
| Ery | $1.24 | −$0.35420 |
| erythromycin | $2.86 | +$1.27 |
| Erythromycin | $2.87 | +$1.28 |
| Erythromycin | $2.97 | +$1.38 |
| ERY-TAB | $2.97 | +$1.38 |
| erythromycin | $5.96 | +$4.37 |
Medicare Part D coverage · CY2026
On 104 plan formularies · typical tier 4
Prior auth 0% · Step therapy 0% · Quantity limit 0% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.